•
Jul 31, 2023

Donaldson Q4 2023 Earnings Report

Donaldson reported a decrease in fourth quarter sales by 1.2% compared to fiscal 2022, but full-year sales increased by 3.8%.

Key Takeaways

Donaldson reported GAAP net earnings of $91.9 million for the fourth quarter and $358.8 million for the full year. Fourth quarter sales decreased by 1.2%. The company provided fiscal year 2024 sales guidance of 3% to 7% growth and EPS outlook of $3.14 to $3.30.

Fourth quarter sales decreased 1.2% compared to fiscal 2022.

Full-year sales increased 3.8%.

Fourth quarter GAAP EPS was $0.75.

Fourth quarter adjusted EPS was $0.78.

Total Revenue
$880M
Previous year: $890M
-1.2%
EPS
$0.78
Previous year: $0.84
-7.1%
Operating Margin
13.7%
Previous year: 14.5%
-5.5%
Gross Margin
34.1%
Previous year: 32.8%
+4.0%
Effective Tax Rate
21.7%
Previous year: 21.4%
+1.4%
Gross Profit
$300M
Previous year: $292M
+2.9%
Cash and Equivalents
$187M
Previous year: $193M
-3.2%
Free Cash Flow
$165M
Previous year: $80.2M
+105.9%
Total Assets
$2.77B
Previous year: $2.6B
+6.5%

Donaldson

Donaldson

Forward Guidance

Full-year EPS is expected to be between $3.14 and $3.30. Sales are projected to increase between 3% and 7% over prior year.

Positive Outlook

  • Mobile sales are forecast to increase between 1% and 5% year over year.
  • Aftermarket sales are projected to increase mid-single digits as a result of higher vehicle utilization rates and market share gains.
  • Industrial sales are expected to grow between 3% and 7% versus 2023.
  • IFS sales are forecast to increase mid-single digits with strength across most businesses, including dust collection and industrial services.
  • Life Sciences sales are forecast to grow approximately 20% compared with prior year benefitting from an increase in sales in all businesses including Food & Beverage, Bioprocessing Equipment and Consumables, and Disk Drive.

Challenges Ahead

  • Aerospace and Defense sales are projected to decrease low-single digits after cycling difficult comparisons in 2023.
  • Investments in the Life Sciences segment will partially offset increasing gross margin.
  • Effective income tax rate of between 24 and 26% is expected.
  • Capital expenditures are forecast to be between $95 million and $115 million.
  • Unspecified ongoing investments are expected.